Session Time: 3:15pm-4:45pm
Presentation Time: 4:15pm-4:27pm
*Purpose: Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication in organ transplant recipients. The use of T lymphocyte-depleting antibodies (TLDAb), especially rabbit TLDAb contributes to PTLD and the V158F polymorphism of Fc gamma receptor IIIA (FcγRIIIA) also named CD16A could affect the concentration-effect relationship of TLDAb. We therefore investigated the association of this polymorphism with PTLD in kidney transplant recipients.
*Methods: We characterized the V158F polymorphism in two case-control cohorts (discovery, n=196; validation, n=222). Then, we evaluated the binding of rabbit IgG to human FcγRIIIA-158V and -158F.
*Results: The V158F polymorphism was not linked to PTLD in the overall cohorts, but risk of PTLD was increased in VV homozygous recipients receiving TLDAb compared to F carriers in both cohorts, especially in recipients receiving TLDAb without muromonab (discovery: HR=2.22 [1.03-4.76], p=0.043, validation: HR=1.75 [1.01-3.13], p=0.049). In vitro, we found that the binding of rabbit IgG to human NK cell FcγRIIIA was increased when cells expressed the 158-V versus the 158-F allotype.
*Conclusions: While the 158-V allotype of human FcγRIIIA binds rabbit immunoglobulin-G with higher affinity, the risk of PTLD was increased in homozygous VV kidney transplant recipients receiving polyclonal TLDAb.
To cite this abstract in AMA style:Gatault P, Lajoie L, Stojanova J, Marquet P, Thibault G. The FcγRIIIa-158 VV Genotype Increased the Risk of Post-Transplant Lymphoproliferative Disorder in T-Cell Depleted Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-fc%ce%b3riiia-158-vv-genotype-increased-the-risk-of-post-transplant-lymphoproliferative-disorder-in-t-cell-depleted-kidney-transplant-recipients/. Accessed October 28, 2020.
« Back to 2020 American Transplant Congress